

华堂宁® Approved in China for T2D



控制血糖
稳而有道



Disclaimer



This document may contain statements that constitute “forward-looking statements”, including, but not limited to, statements relating to the implementation of strategic initiatives, and other statements relating to our future business development and economic performance.

While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other statutory requirements may render actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, (1) general market, macro-economy, governmental and regulatory trends, (2) movements in local and international securities markets, currency exchange rates and interest rates, (3) competitive pressures, (4) technological developments, (5) changes in the financial position or creditworthiness of our customers, partners, vendors obligors and counterparts, and changes in the developments in the markets in which they operate, (6) legislative or regulatory developments, (7) management changes and changes to our business group structure and (8) other key factors that may adversely affect our business and financial model.

We are not under any obligation to (and expressly disclaim any such obligations to) update or alter forward-looking statements whether as a result of new information, future events, or otherwise.

This material may not be reproduced, distributed or transmitted to any other person or incorporated in any way into another document or other material without the prior written consent of us.

This document is not:


- (a) an offer of securities for sale in Hong Kong or elsewhere; or
- (b) an invitation to enter into an agreement to acquire, dispose of, subscribe for or underwrite securities; or related to the issue of any securities.

All documents and conference contents are for institutional investors, no unauthorized audio and video recordings and may not be directly or indirectly reproduced even modified, redistributed or forwarded to any other person and may not be published in whole or in part for any purpose.

Dorzagliatin 华堂宁® Approved by NMPA



1. One Breakthrough: restore the impaired glucose homeostasis in T2D patients
2. Two Indications: with dietary and exercise to treat
 1. drug naïve T2D
 2. Metformin tolerated T2D
3. Three Allowances
 1. No dose adjustment for DKD
 2. No dose adjustment when combined with sitagliptin
 3. No dose adjustment when combined with empagliflozin




多格列艾汀片 华领医药技术（上海）有限公司 国药准字H20220024
华堂宁® webpage: <https://www.huamedicine.com/HuaTangNing>

Glucose Homeostasis to Advance Diabetes Care



Prevention, Remission and Rejuvenation



Future Direction for Diabetes Management

- **Diabetes remission** for drug naïve T2D
- **Diabetes prevention** on impaired glucose tolerance
- **Diabetes rejuvenation** to prevent diabetes complication

* IDF Diabetes Atlas 10th Edit; Leon Litwak Diabetology & Metabolic Syndrome 2013, 5: 57; Yuanyuan Cheng, Li Chen Global J Obesity, Diabetes and Metabolic Syndrome 2020, 7: 18